• Mutation; HGNC; HGNC:3691; FGFR4; Simple; p.Val550Leu (c.1648G>C); Zygosity=Unspecified (PubMed=22142829).
  

PubMed=12370270; DOI=10.1172/JCI15634; PMCID=PMC151148
Dipak Panigrahy, Samuel Singer, Lucy Q. Shen, Catherine E. Butterfield, Deborah A. Freedman, Emy J. Chen, Marsha A. Moses, Susan Kilroy, Stefan Duensing, Christopher David Marsden Fletcher, Jonathan A. Fletcher ...Show all 15 authors... , Lynn Hlatky, Philip Hahnfeldt, Judah Folkman, Arja Kaipainen; Show fewer authors
PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis.
J. Clin. Invest. 110:923-932(2002)

PubMed=22142829; DOI=10.1158/1078-0432.CCR-11-2056; PMCID=PMC3271129
Neerav Shukla, Nabahet Ameur, Ismail Yilmaz, Khedoudja Nafa, Chyau-Yueh Lau, Angela Marchetti, Laetitia Borsu, Frederic G. Barr, Marc Ladanyi;
Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways.
Clin. Cancer Res. 18:748-757(2012)

PubMed=23882450; DOI=10.3389/fonc.2013.00183; PMCID=PMC3713458
Ashley R.P. Hinson, Rosanne Jones, Lisa E.S. Crose, Brian C. Belyea, Frederic G. Barr, Corinne Mary Linardic;
Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research: utility and pitfalls.
Front. Oncol. 3:183.1-183.12(2013)

PubMed=23665679; DOI=10.1038/onc.2013.129
Elizabeth I. Sokolowski, Claire B. Turina, Ken Kikuchi, David M. Langenau, Charles Keller;
Proof-of-concept rare cancers in drug development: the case for rhabdomyosarcoma.
Oncogene 33:1877-1889(2014)